Found: 35
Select item for more details and to access through your institution.
Design and development of the theranostic pair <sup>177</sup>Lu‐OPS201/<sup>68</sup>Ga‐OPS202 for targeting somatostatin receptor expressing tumors.
- Published in:
- Journal of Labelled Compounds & Radiopharmaceuticals, 2019, v. 62, n. 10, p. 635, doi. 10.1002/jlcr.3755
- By:
- Publication type:
- Article
Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists.
- Published in:
- Pharmaceuticals (14248247), 2023, v. 16, n. 5, p. 674, doi. 10.3390/ph16050674
- By:
- Publication type:
- Article
Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [ 177 Lu]Lu-Satoreotide Tetraxetan and the Agonist [ 177 Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST 2 -Positive Tumours.
- Published in:
- Pharmaceuticals (14248247), 2022, v. 15, n. 9, p. N.PAG, doi. 10.3390/ph15091085
- By:
- Publication type:
- Article
Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [ 177 Lu]Lu-OPS201 Compared to the Agonist [ 177 Lu]Lu-DOTA-TATE.
- Published in:
- Pharmaceuticals (14248247), 2021, v. 14, n. 12, p. 1265, doi. 10.3390/ph14121265
- By:
- Publication type:
- Article
SPECT Imaging of SST2-Expressing Tumors with 99m Tc-Based Somatostatin Receptor Antagonists: The Role of Tetraamine, HYNIC, and Spacers.
- Published in:
- Pharmaceuticals (14248247), 2021, v. 14, n. 4, p. 300, doi. 10.3390/ph14040300
- By:
- Publication type:
- Article
Selection of the First 99m Tc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates.
- Published in:
- Pharmaceuticals (14248247), 2021, v. 14, n. 1, p. 19, doi. 10.3390/ph14010019
- By:
- Publication type:
- Article
In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [<sup>177</sup>Lu]Lu-PP-F11N in humans: the lumed phase 0b study.
- Published in:
- EJNMMI Research, 2024, v. 14, n. 1, p. 1, doi. 10.1186/s13550-024-01101-w
- By:
- Publication type:
- Article
Radiolabeled peptides and their expanding role in clinical imaging and targeted cancer therapy.
- Published in:
- Journal of Peptide Science, 2024, v. 30, n. 10, p. 1, doi. 10.1002/psc.3607
- By:
- Publication type:
- Article
Radiolabeled Somatostatin Analogs—A Continuously Evolving Class of Radiopharmaceuticals.
- Published in:
- Cancers, 2022, v. 14, n. 5, p. 1172, doi. 10.3390/cancers14051172
- By:
- Publication type:
- Article
Radiolabeled Bombesin Analogs.
- Published in:
- Cancers, 2021, v. 13, n. 22, p. 5766, doi. 10.3390/cancers13225766
- By:
- Publication type:
- Article
Self-assembled or mixed peptide amphiphile micelles from Herpes simplex virus glycoproteins as potential immunomodulatory treatment.
- Published in:
- International Journal of Nanomedicine, 2014, v. 9, p. 2137, doi. 10.2147/IJN.S57656
- By:
- Publication type:
- Article
Copper-61 is an advantageous alternative to gallium-68 for PET imaging of somatostatin receptor-expressing tumors: a head-to-head comparative preclinical study.
- Published in:
- Frontiers in Nuclear Medicine, 2024, p. 1, doi. 10.3389/fnume.2024.1481343
- By:
- Publication type:
- Article
A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting.
- Published in:
- EJNMMI Research, 2020, v. 10, n. 1, p. 1, doi. 10.1186/s13550-020-00677-3
- By:
- Publication type:
- Article
CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (<sup>123/131</sup>I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors.
- Published in:
- Journal of Translational Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12967-023-04466-z
- By:
- Publication type:
- Article
Comparison of the binding and internalization properties of 12 DOTA-coupled and In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2011, v. 38, n. 8, p. 1417, doi. 10.1007/s00259-011-1816-y
- By:
- Publication type:
- Article
Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2011, v. 38, n. 1, p. 97, doi. 10.1007/s00259-010-1596-9
- By:
- Publication type:
- Article
Pre-clinical evaluation of eight DOTA coupled gastrin-releasing peptide receptor (GRP-R) ligands for in vivo targeting of receptor-expressing tumors.
- Published in:
- EJNMMI Research, 2016, v. 6, n. 1, p. 1, doi. 10.1186/s13550-016-0175-x
- By:
- Publication type:
- Article
Influence of d-glutamine and d-glutamic acid sequences in optical peptide probes targeted against the cholecystokinin-2/gastrin-receptor on binding affinity, specificity and pharmacokinetic properties.
- Published in:
- EJNMMI Research, 2013, v. 3, n. 1, p. 1, doi. 10.1186/2191-219X-3-75
- By:
- Publication type:
- Article
<sup>61</sup>Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 8, p. 1, doi. 10.2967/jnumed.123.267126
- By:
- Publication type:
- Article
Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog <sup>177</sup>Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution?
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 3, p. 393, doi. 10.2967/jnumed.118.207845
- By:
- Publication type:
- Article
Biodistribution, Pharmacokinetics, and Dosimetry of <sup>177</sup>Lu-, <sup>90</sup>Y-, and <sup>111</sup>In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist <sup>177</sup>Lu-DOTATATE: The Mass Effect.
- Published in:
- Journal of Nuclear Medicine, 2017, v. 58, n. 9, p. 1435, doi. 10.2967/jnumed.117.191684
- By:
- Publication type:
- Article
Bombesin-Targeted PET of Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2016, v. 57, p. 67S, doi. 10.2967/jnumed.115.170977
- By:
- Publication type:
- Article
Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic Tracers.
- Published in:
- Journal of Nuclear Medicine, 2016, v. 57, n. 8, p. 1282, doi. 10.2967/jnumed.115.168948
- By:
- Publication type:
- Article
N-Terminal Modifications Improve the Receptor Affinity and Pharmacokinetics of Radiolabeled Peptidic Gastrin-Releasing Peptide Receptor Antagonists: Examples of <sup>68</sup>Ga- and <sup>64</sup>Cu-Labeled Peptides for PET Imaging.
- Published in:
- Journal of Nuclear Medicine, 2014, v. 55, n. 10, p. 1719, doi. 10.2967/jnumed.114.141242
- By:
- Publication type:
- Article
Targeted Radiotherapy of Prostate Cancer with a Gastrin-Releasing Peptide Receptor Antagonist Is Effective as Monotherapy and in Combination with Rapamycin.
- Published in:
- Journal of Nuclear Medicine, 2013, v. 54, n. 5, p. 762, doi. 10.2967/jnumed.112.112169
- By:
- Publication type:
- Article
Bombesin Antagonist--Based Radioligands for Translational Nuclear Imaging of Gastrin-Releasing Peptide Receptor--Positive Tumors.
- Published in:
- Journal of Nuclear Medicine, 2011, v. 52, n. 12, p. 1970, doi. 10.2967/jnumed.111.094375
- By:
- Publication type:
- Article
PET of Somatostatin Receptor--Positive Tumors Using <sup>64</sup>Cu- and <sup>68</sup>Ga-Somatostatin Antagonists: The Chelate Makes the Difference.
- Published in:
- Journal of Nuclear Medicine, 2011, v. 52, n. 7, p. 1110, doi. 10.2967/jnumed.111.087999
- By:
- Publication type:
- Article
Exendin-4-Based Radiopharmaceuticals for Glucagonlike Peptide-1 Receptor PET/CT and SPECT/CT.
- Published in:
- Journal of Nuclear Medicine, 2010, v. 51, n. 7, p. 1059, doi. 10.2967/jnumed.110.074914
- By:
- Publication type:
- Article
Tetraamine-Derived Bifunctional Chelators for Technetium-99m Labelling: Synthesis, Bioconjugation and Evaluation as Targeted SPECT Imaging Probes for GRP-Receptor-Positive Tumours.
- Published in:
- Chemistry - A European Journal, 2010, v. 16, n. 7, p. 2115, doi. 10.1002/chem.200902011
- By:
- Publication type:
- Article
Peptide-chelating agent conjugate for selective targeting of somatostatin receptor type 1: Synthesis and characterization.
- Published in:
- Biopolymers, 2004, v. 76, n. 6, p. 527, doi. 10.1002/bip.20169
- By:
- Publication type:
- Article
Evaluation of a New 177Lu-Labeled Somatostatin Analog for the Treatment of Tumors Expressing Somatostatin Receptor Subtypes 2 and 5.
- Published in:
- Molecules, 2020, v. 25, n. 18, p. 4155, doi. 10.3390/molecules25184155
- By:
- Publication type:
- Article
Radiolabeled Peptides for Cancer Imaging and Therapy: From Bench-to-Bedside.
- Published in:
- Chimia, 2021, v. 75, n. 6, p. 500, doi. 10.2533/chimia.2021.500
- By:
- Publication type:
- Article
Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 3050, doi. 10.1007/s00259-023-06272-7
- By:
- Publication type:
- Article
Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist Ga-RM2: Preliminary results in patients with negative or inconclusive [F]Fluoroethylcholine-PET/CT.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2017, v. 44, n. 9, p. 1463, doi. 10.1007/s00259-017-3702-8
- By:
- Publication type:
- Article
Criteria for the Design and Biological Characterization of Radiolabeled Peptide-Based Pharmaceuticals.
- Published in:
- BioDrugs, 2004, v. 18, n. 5, p. 279, doi. 10.2165/00063030-200418050-00001
- By:
- Publication type:
- Article